CMTDIE

INF2 | 2011

What Is CMTDIE?

CMTDIE is a type of CMT caused by autosomal dominant mutations in the INF2 gene. This gene provides instructions for making inverted formin-2, a protein involved in regulating the actin cytoskeleton within cells. Mutations in the INF2 gene disrupt this function, leading to impaired nerve signal transmission.

CMTDIE is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

The age of symptom onset in CMTDIE is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities, consistent with an intermediate form of CMT.

CMTDIE symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMTDIE shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMTDIE

Classification
CMTDI

Neuropathy Type
Intermediate

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
INF2

Gene Full Name
inverted formin 2

Chromosome
14q32.33

Zygosity of Responsible Variant
Heterozygous

Mitochondrial Involvement
Yes

Variant Mechanism

Toxic Gain of Function (GoF)

Details

Mechanistic basis:
Overactivity

Confidence:
Medium

Prediction:
The literature predicts a gain-of-function mechanism for CMTDIE: the dominant missense variants cluster in the N-terminal diaphanous-inhibitory domain and break the intramolecular DID-DAD contact that holds INF2 in its autoinhibited state, leaving the formin constitutively competent to polymerize actin and to drive ER-actin-dependent mitochondrial fission. The same DID allele class also produces focal segmental glomerulosclerosis, which fits an activating lesion rather than reduced INF2 dosage.

Rationale:
Releasing the autoinhibitory clamp leaves the mutant formin doing more of INF2's own job, unregulated actin assembly and the mitochondrial fission that depends on it, with no requirement that the wild-type allele be affected. Whether mutant subunits additionally alter normal INF2 within dimers has not been settled, and confidence sits at medium for that reason.

ClinVar Pathogenic Variants

View INF2 ClinVar Variants

CMTDIE OMIM Entry

CMTDIE OMIM

INF2 OMIM Entry

INF2 OMIM

More Info

CMTDIE Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

INF2 Mutations in Charcot-Marie-Tooth Disease with Glomerulopathy

Authors

Boyer, O., Nevo, F., Plaisier, E., Funalot, B., Gribouval, O., Benoit, G., Huynh Cong, E., Arrondel, C., Tête, M. J., Montjean, R., Richard, L., Karras, A., Pouteil-Noble, C., Balafrej, L., Bonnardeaux, A., Canaud, G., Charasse, C., Dantal, J., Deschenes, G., Deteix, P., … Mollet, G.

Publication Date
December 22, 2011

Updated: August 8, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.